Solventum Corporation $SOLV Stock Holdings Raised by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in Solventum Corporation (NYSE:SOLV) by 147.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,700 shares of the company’s stock after purchasing an additional 19,500 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Solventum were worth $2,883,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of SOLV. Choreo LLC increased its stake in shares of Solventum by 2.9% during the third quarter. Choreo LLC now owns 12,910 shares of the company’s stock worth $1,138,000 after purchasing an additional 368 shares in the last quarter. Motley Fool Asset Management LLC lifted its stake in Solventum by 43.8% in the 3rd quarter. Motley Fool Asset Management LLC now owns 5,109 shares of the company’s stock valued at $450,000 after buying an additional 1,555 shares in the last quarter. North Dakota State Investment Board lifted its stake in Solventum by 3.1% in the 3rd quarter. North Dakota State Investment Board now owns 4,525 shares of the company’s stock valued at $399,000 after buying an additional 134 shares in the last quarter. Laurel Wealth Advisors LLC purchased a new position in Solventum in the 3rd quarter valued at about $29,000. Finally, Busey Bank boosted its holdings in Solventum by 13.8% in the 3rd quarter. Busey Bank now owns 3,231 shares of the company’s stock worth $285,000 after buying an additional 393 shares during the last quarter.

Analyst Upgrades and Downgrades

SOLV has been the topic of a number of research reports. Weiss Ratings upgraded Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. UBS Group upped their target price on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wedbush upped their target price on shares of Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. KeyCorp increased their target price on shares of Solventum from $93.00 to $102.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, Stifel Nicolaus raised their price target on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $87.55.

Solventum Price Performance

Solventum stock opened at $84.52 on Tuesday. The company’s 50 day simple moving average is $88.02 and its 200-day simple moving average is $78.54. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.74 and a current ratio of 1.02. Solventum Corporation has a 1 year low of $62.38 and a 1 year high of $94.16. The company has a market capitalization of $14.39 billion, a price-to-earnings ratio of 11.53, a price-to-earnings-growth ratio of 1.20 and a beta of 0.63.

Solventum (NYSE:SOLV) last posted its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%. The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the prior year, the company earned $1.69 EPS. Solventum’s revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, equities research analysts expect that Solventum Corporation will post 7.20 earnings per share for the current year.

Solventum Company Profile

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.